- Novo Nordisk suspended from ABPI for 2 years over serious breaches of code of practice.
- Complaint alleges that Novo sponsored courses on weight management without disclosing involvement.
- ABPI panel concludes that funding for health professionals was linked to promotion of drug Saxenda.
- Novo to undergo audits in 2023 and 2024 to show sustained improvement for resuming membership.
Novo Nordisk suspended from UK lobby group
Danish drugmaker Novo Nordisk has been suspended from the Association of the British Pharmaceutical Industry (ABPI) for two years over what the ABPI on Thursday described as "serious breaches" of its code of practice.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/QS2HKPIG5VJDPCACOJA74BEON4.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/UQPIK3T2DVOX7EIO4QZCM5HIAA.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/ZJM34EMBWJO7BKLC32OVFVZECQ.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/75ZPE5KGUZKI7JLZHA3YCDVDVA.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/VAKMASTY6JJC5EBSX4MM5OEQKM.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/RCWZE2OK3BNCJNRVFOS74NYF7M.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/6W5WJY7T4NLKVFJO5JX37LPYS4.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/BYL7ESQPMFMSNNVJSVCYKYTPH4.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/OGBROYPEZVMVNLCKMBDIE2XJCE.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/JG3AL7UAGVPBJHJUNQS4YZL4SE.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/QS2HKPIG5VJDPCACOJA74BEON4.jpg&description=Novo%20Nordisk%20suspended%20from%20UK%20lobby%20group){kind=link}